RxDoctor Payments Data

Ziyi Wang, MD

Family Medicine · Farmington, UTNPI 1255781654

Payments from drug & device makers

$5,534in general payments, 2019–2025

Across 340 payments — averaging $16.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$613
  • Lilly USA, LLC$467
  • Amgen$440
  • Boehringer Ingelheim$330
  • GSK$323
  • Johnson & Johnson$247
  • plus $3K from 46 others
$500in research payments, 2019–2025

Across 1 payment — averaging $500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Lucid Diagnostics Inc.$500

What the payments were for

  • Food & beverage$5,534100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,534 in reported general payments places this provider in the 80th percentile of 928 family medicine providers in Utah.

See all family medicine providers in Utah

Medicare billing

Part B allowed, 2024
$31,916
Medicare patients
56
Services billed
385

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide57$71,735
EliquisApixaban37$52,209
OzempicSemaglutide34$34,624
FarxigaDapagliflozin Propanediol15$25,696
Humalog Kwikpen U-200Insulin Lispro12$20,264
XareltoRivaroxaban18$17,585
Lantus SolostarInsulin Glargine,hum.Rec.Anlog23$3,014
Omeprazole122$2,684
Levothyroxine Sodium177$1,886
Estradiol (Once Weekly)Estradiol14$1,772
Atorvastatin Calcium139$1,462
Estradiol27$1,455
Gabapentin69$1,218
Potassium Chloride48$1,115
Losartan Potassium108$973

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$467$71,73557 claims
PfizerEliquis$118$52,20937 claims
Novo NordiskOzempic$193$34,62434 claims
AstraZenecaFarxiga$132$25,69615 claims
Johnson & JohnsonXarelto$247$17,58518 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$46$1,886177 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 928 family medicine providers in Utah.

Other family medicine in Farmington

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →